The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...

Last week, the FDA determined the shortage of Eli Lilly tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, ...

WHAT TO KNOW ABOUT GLP-1 SHORTAGES — It’s been a busy week in the diabetes and weight-loss drug world as Eli Lilly renews its push to shut down the compounding of its tirzepatide products and the ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...